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Multiple  small-molecule  kinase  inhibitors  with  specific  molecular  targets  have  recently  been  developed
for  the  treatment  of  cancer.  This  article  reports  the  development  and  validation  of  an  ultra-performance
liquid  chromatography/tandem  mass  spectrometry  (UPLC–MS/MS)  method  to  simultaneously  analyse
the  small-molecule  kinase  inhibitors  dacomitinib,  ceritinib,  lorlatinib,  and  nintedanib  in  human  plasma.
For chromatographic  analyte  separation,  an  Acquity  UPLC® BEH  C18 column  1.7  m, 50  mm  x  2.1  mm
was  used  with  a binary  gradient  of  pure  water/formic  acid/ammonium  formate  (100:0.1:0.02,  v/v/v)  and
methanol/formic  acid  (100:0.1,  v/v).  Calibration  curves  for  all small-molecule  kinase  inhibitors  wereSmall-molecule kinase inhibitor (SMKI)
Ceritinib
Dacomitinib
Lorlatinib
Nintedanib
Ultra-performance liquid chromatography
5.00–500  ng/mL.  Validation  of  this  method  met  all requirements  of  the  Food  and  Drug  administra-
tion. Additionally,  clinical  applicability  was  demonstrated  by quantification  of  multiple  samples  from
a pharmacokinetic  study  in  patients  with  lung  cancer.
©  2020  The  Author(s).  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Small-molecule kinase inhibitors (SMKIs) are one of the back-
bones in the treatment of cancer. They are developed to specifically
block dysregulated protein tyrosine kinases in tumour cells. [1]
Treatment with SMKIs is standard of care for various types of solid
and hematologic malignancies. Over the last years, their number
has vastly increased. Because of their specificity, most SMKIs are
prescribed based on molecular characteristics of a tumour.
In non-small cell lung cancer (NSCLC), the most frequent molec-
ular driver aberrations are epidermal growth factor receptor (EGFR)
mutations and anaplastic lymphoma kinase (ALK) translocations.
Together, they represent 10–20% of all NSCLC patients, with higher
incidences in Asia than in the rest of the world. [2] Dacomitinib is an
oral SMKI registered for EGFR mutated NSCLC [3]. Both ceritinib and
lorlatinib are SMKIs specifically targeting ALK mutations in NSCLC
∗ Corresponding author at: Department of Medical Oncology, Laboratory of Trans-
lational Pharmacology, Erasmus University Medical Centre, PO box 2040, 3000 CB,
Rotterdam, The Netherlands.
E-mail address: g.veerman@erasmusmc.nl (G.D.M. Veerman).
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0731-7085/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article3]. All three SMKIs are administered once daily [3]. Nintedanib
s a vascular endothelial growth factor (VEGF) receptor inhibitor
pproved in combination with docetaxel for second line treatment
f patients with NSCLC. This treatment however, is independent
f mutational status and is dosed in a twice-daily schedule of 200
g. [3] Combinations of these four SMKIs have not been reported
nd based on the specific indications of each drug, combination
reatment is not expected.
Also in other fields of medicine, SMKIs are registered for progres-
ive diseases in which cell proliferation is unwanted. Nintedanib for
xample, has an additional approval for treatment of progressive
ung fibrosis. Contrary to its use in medical oncology, nintedanib is
egistered as monotherapy and administered 150 mg  twice daily.
3]
Multiple SMKIs are known to have specific target plasma con-
entrations and a narrow therapeutic window. [4] Even though oral
dministration of SMKIs has its benefits, it additionally increases
he intra- and interpatient variability. Due to interactions with
oadministered drugs [5], food, and beverages [6,7] drug absorp-
ion and metabolism could be altered. Subsequent increase in drug
oncentration above the therapeutic window could lead to (severe)
 under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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toxicity, where effectiveness of treatment is compromised when
the target concentration is not reached.
In order to investigate the therapeutic window of SMKIs,
compounds that could interact with them, and ultimately
performing therapeutic drug monitoring (TDM), a liquid chro-
matography/tandem mass spectrometric (LC–MS/MS) assay for
drug quantification has to be developed and validated. There are
multiple LC–MS/MS assays published which separately report the
quantification of ceritinib, [8–12] dacomitinib [13], lorlatinib [14],
or nintedanib [15–17] in plasma. For dacomitinib and lorlatinib
however, these methods were only developed for non-human
plasma. We here describe the development and full validation
according to U.S. Food & Drug Administration guidelines [18] of
an LC–MS/MS method for the simultaneous quantification of the
SMKIs ceritinib, dacomitinib, lorlatinib, and nintedanib in human
plasma.
2. Material and methods
2.1. Chemicals
Ceritinib (C28H36ClN5O3S) was acquired from Toronto Research
Chemicals (North York, Canada), dacomitinib (C24H25ClFN5O2)
at Sigma-Aldrich (Saint Louis, USA), lorlatinib (C21H19FN6O2)
at MedChemExpress (Monmouth Junction, USA) and nintedanib
(C31H33N5O4C28H33N7O2) at LC Laboratories (Woburn, USA).
The purity of all SMKIs was 98 % or higher. Labeled inter-
nal standard dasatinib-d8 was purchased at Toronto Research
Chemicals (Toronto, Canada). Blanc human lithium heparinized
plasma was bought at BioIVT (Seralab), (West Sussex, United
Kingdom). Dimethylsulfoxide (DMSO) and ammonium formate
(1 mol/L) was obtained from Sigma-Aldrich. Acetonitrile, pure
water and methanol originated from Biosolve (Valkenswaard, The
Netherlands). Formic acid was purchased from JT Baker (Deven-
ter, The Netherlands). These chemicals were of analytical grade
or higher. Nitrogen originated from LindeGas (Schiedam, The
Netherlands).
2.2. Calibration
Ceritinib, dacomitinib, lorlatinib, and nintedanib were dissolved
in DMSO to create three stock solutions of 1.00 mg/mL  (inter-stock
deviation < 5 %). One was used to prepare Quality Control (QC)
samples and one was used to form calibration curve standards. Sep-
arately, dasatinib-d6 was dissolved in DMSO to make a solution of
1.0 mg/mL. Acetonitrile was hereafter used to dilute 10,000-fold to
create a working solution of 100 ng/mL dasatinib-d6. Calibration
standards with the four SMKI concentrations of 5.00, 12.5, 25.0,
50.0, 125, 250, 450 and 500 ng/mL were prepared in human lithium
heparinized plasma. QC samples were made to yield final concen-
trations of 5.00 (lower limit of quantification; LLQ), 15.0 (QC-low),
100 (QC-middle), 400 (QC-high) and 8,000 (QC-diluted) ng/mL. The
QC-diluted samples were subsequently diluted prior to processing
in human plasma to the level of 400 ng/mL. All stock solutions,
internal standard solution, and pools of QC samples were stored at
T < -70 ◦C. Internal standard working solution was kept at T < 6 ◦C
for a maximum of three months.
2.3. Sample pre-treatment
Twenty-five L plasma of every sample was combined with 100
L internal standard solution in a 1.5 mL  vial. Solutions were 5
s mixed and 10 min  centrifuged at 18,000 g. Hereafter, 50 L of
the supernatant was transferred to a 96-deepwell plate, to which
100 L water/formic acid/ammonium formate (100:0.1:0.02, v/v/v)
was added. After 5 min  shaking, the plate was positioned in
2
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he chilled autosampler. Aliquots of 5 L were injected onto the
C–MS/MS column.
.4. LC –MS/MS system
The ultra-performance LC–MS/MS system originated from
aters Chromatography BV (Etten-Leur, the Netherlands) was con-
isted of a Waters Acquity UPLC I-Class Binary Solvent Manager
onnecting a Waters XEVO TQ-S Micro Detector.
.4.1. Data processing
MassLynx version 4.1 SP4 was used for the collecting, processing
nd displaying of data. TargetLynx software calculated and quanti-
ed all samples.
.4.2. Chromatographic settings
For chromatographic analyte separation, the Acquity UPLC® BEH
18 column 1.7 m,  50 mm x 2.1 mm  (Waters Chromatography
V) was warmed to T =40 ◦C. Column flow rate was  0.350 mL/min
ith a binary gradient of mobile phase A which consisted of pure
ater/formic acid/ammonium formate (100:0.1:0.02, v/v/v) and
obile phase B which consisted of methanol/formic acid (100:0.1,
/v). After injection, separation was yield by linearly increasing
hase B from 15 % to 60 % from 1.00 min  to 5.00 min. In 30 s, mobile
hase B increased to 90 % and after 2.50 min, it linearly decreased
o 15 % in 30 s. During the last 1.50 min  of the overall processing
ime of 10.0 min, mobile phase B remained at 15 %. Hereafter, the
njection needle was washed with a strong organic mixture con-
aining acetonitrile, methanol, 2-propanol, water and formic acid
25:25:25:25:0.1, v/v/v/v/v) to prevent carry-over.
.4.3. Tandem mass spectrometry
Tandem mass spectrometry (MS/MS) was  performed in the elec-
rospray positive ionization mode. Capillary ion voltage was set at
.00 kV and the source temperature was set at 150 ◦C. Desolva-
ion temperature was set at 650 ◦C while nitrogen was  used as
esolvation gas at a flow rate of 1,200 l/h. Collision cell Pirani pres-
ure was  kept at ∼4.5e-3 mbar by argon gas. Mass transitions of
eritinib, dacomitinib, lorlatinib and nintedanib and the internal
tandard dasatinib-d8 were performed by direct infusion after dis-
olving all compounds in acetonitrile/water/formic acid (40:60:0.1,
/v/v). The six mass pairs were quantified during multiple reaction
onitoring. The MS/MS  functions were manually adjusted to obtain
he optimal parameters which are presented in Table 1.
.4.4. Quantification
Peak area ratios per SMKI compared to the internal standard
ere used in order to from calibration curves; ceritinib (558 > 433),
acomitinib (470 > 124), lorlatinib (407 > 228) and nintedanib (540
 113) to dasatinib-d8 (496 > 406) with a 1/concentration2 weight
actor.
.5. Validation
The method has been validated according to the latest U.S. Food
 Drug Administration (FDA) guidelines. [18]
.5.1. Specificity and selectivity
The specificity and selectivity of this assay were tested at the
evel of the LLQ (5.00 ng/mL) for which 10 sets of single blank
uman plasma were spiked. All samples were analysed simulta-
eously..5.2. Accuracy, precision and matrix effect
Five sets of LLQ and QC samples were analysed in three succes-
ive runs, which were preceded and finished by a set of calibration
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Table  1
Mass spectrometry settings for multiple reaction monitoring.
Compound Parent (m/z) Daughter (m/z) Dwell (msec) Cone (V) Collision (V)
Ceritinib 558 433 54 23 29
Ceritinib 558 516 54 25 24
Dacomitinib 470 124 54 20 34
Lorlatinib 407 228 54 35 21
Nintedanib 540 113 54 10 28
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Transitions used for the quantitation are presented in bold.
curve standards. To calculate the assay’s accuracy, within-run and
between-run precision, a unidirectional analysis of variance (one-
way ANOVA analysis) was  run, with the cycle as variable. [19] The
matrix effect was tested in triplicate with the post-extraction addi-
tion method: six blank plasma samples underwent preparation and
extraction, where after they were spiked at QC low (15.0 ng/mL) and
QC high (400 ng/mL) for all SMKIs (A). A neat solvent standard solu-
tion served as reference (B). After analysing all samples, the matrix
effect could be quantified by BA x 100 %.
2.5.3. Stability
Stability of ceritinib, dacomitinib, lorlatinib and nintedanib in
plasma was tested at concentration levels of QC-low, QC-high
and QC-diluted. QC samples (in triplicate) were stored at ambi-
ent temperature for a three-day period as well as following three
freeze-thaw cycles at which the samples were thawed in a water-
bath at 37 ◦C for 30 min  and refreeze for at least 18 h at < -70 ◦C.
Autosampler stability was tested in triplicate by repeated injection
of processed QC-samples stored in a chilled autosampler at 10 ◦C.
2.6. Clinical applicability
The assay’s clinical applicability was demonstrated by analysing
plasma samples from patients treated with ceritinib, lorlatinib and
nintedanib. These samples were prospectively collected as part of a
large pharmacokinetic study in which patients treated with all dif-
ferent SMKIs were included. In order to measure all SMKIs, another
LC–MS/MS method has also been developed. [20] The study has
been approved by the local ethics committee of the Erasmus MC
(MEC 16–643) and patients provided written informed consent
prior to study enrolment. Samples were taken after six or twelve
weeks of treatment to guarantee steady state plasma concentra-
tions. Patients was asked to wait with SMKI intake until after blood
withdrawal, in order to determine plasma trough concentrations.
Subsequent after collection, samples were centrifuged for 10 min
at 2500 g and 4 ◦C, after which the plasma was kept at – 70 ◦C.
Unfortunately, no patients were treated yet with dacomitinib in
this study.
2.7. Incurred sample reanalysis
In line with the clinical applicability of this assay, incurred
sample reanalysis was tested to ensure the preciseness of study
sample quantification in a second run. Therefore, all used samples
in paragraph 2.6 underwent independent reanalysis. Hereafter, the
relative difference between the first sample concentration (C1) and
the second -repeated- sample concentration (C2) was  calculated
by: (C1 – C2)(C1+C2)
2
∗ 100%.
e
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. Results and discussion
.1. Method development
Combining the optimal mass-spectrometric parameters and
etention times with mobile phase A (pure water/formic
cid/ammonium formate; 100:0.1;0.02, v/v/v) and mobile phase
 (methanol/formic acid; 100:0.1, v/v) at a gradient 0.350 mL/min
ow rate, purest peaks for every SMKI were detected. Selected tran-
itions, proposed fragmentations and ion spectra for these SMKIs
re shown in Fig. 1. Primary to secondary ion ratios demonstrated
he quality for every observed peak. The selected product ions are
resented in Table 1. Dasatinib-d8 was an acceptable internal stan-
ard for all compounds, where other authors report using other
isotope-labelled) internal standards. [8–17] Separation of analyts
as  yielded with a stepped gradient (paragraph 2.4.2). Herewith,
epresentative chromatograms for all SMKIs and internal standard
ere created, as illustrated in Fig. 2. Retention times for ceritinib,
acomitinib, lorlatinib and nintedanib were 5.72, 3.61, 3.33 and
.11 min  respectively. Acetonitrile deproteinisation proved to be a
uccessful method for quantifying ceritinib, dacomitinib, lorlatinib
nd nintedanib in human plasma in the range of 5.00–500 ng/mL.
o avoid carry-over, a wash period of 3 min  of 90 % eluens B was
uilt-in, which led to a total run-time of 10 min.
.2. Assay performance
.2.1. Specificity and selectivity
Calibration curve regression coefficients (R2) were linear from
.00–500 ng/mL and ranged from 0.9967 to 0.9990. The lower limit
f quantitation (5.00 ng/mL) was  validated in ten independent
ools of human plasma and by five measurements repeated in trip-
icate (15 samples in total). For every SMKI, all analysed LLQ samples
ere in the acceptance ranges of accuracy of 80–120%. Blank
uman plasma did neither interfere with the SMKIs nor the internal
tandard. Mean ceritinib concentration was 4.85 ng/mL (standard
eviation; SD 0.259 ng/mL), mean dacomitinib concentration was
.61 ng/mL (SD 0.303 ng/mL), mean lorlatinib concentration was
.59 ng/mL (SD 0.273 ng/mL), and mean nintedanib concentration
as  4.65 ng/mL (SD 0.214 ng/mL).
.2.2. Accuracy, precision and matrix effect
The assay’s accuracy, within-run and between-run precision at
oncentration levels of LLQ and QC low, middle, high and diluted
et  the requirements of validation of the FDA  (LLQ range 80–120
, QC range 85–115 %). [18] All 15 analysed samples for every SMKI
t every concentration fell in these acceptable validation ranges.
he post-extraction addition method with six independent sam-
les at QC low and high showed no evidence for significant matrix
ffect for any SMKI. The matrix effect ranged from 84 to 100 %,
howing no interference of the matrix in this method. The results of
ccuracy, within-run and between-run precision and matrix effect
alculations are presented in Table 2.
G.D.M. Veerman, P. de Bruijn, A.-M.C. Dingemans et al. Journal of Pharmaceutical and Biomedical Analysis 193 (2021) 113733
Fig. 1. Selected transitions, proposed fragmentations and ion spectra for ceritinib (A), dacomitinib (B), lorlatinib (C) and nintedanib (D).
Table 2
Accuracy, within-run precision, between-run precision and matrix effect.
Compound Spiked (ng/mL) Grand Mean (ng/mL) Average Accuracy (%) WRP  (%) BRP (%) Matrix effect1 (%)
Ceritinib
LLQ 5.00 5.44 108.8 12.7 # –
QC  LOW 15.0 15.5 103.3 3.13 5.82 81.9 ± 2.38
QC  MIDDLE 100 104 104.0 2.62 5.36 –
QC  HIGH 400 408 102.0 2.44 4.29 84.1 ± 3.56
QC  DILUTED 8000 7787 97.3 3.01 3.20 –
Dacomitinib
LLQ  5.00 5.24 104.8 2.49 2.35 –
QC  LOW 15.0 14.7 98.0 2.92 1.28 94.7 ± 2.20
QC  MIDDLE 100 95.9 95.9 1.17 0.67 –
QC  HIGH 400 379 94.8 2.18 1.67 97.9 ± 3.13
QC  DILUTED 8000 7308 91.4 3.52 0.94 –
Lorlatinib
LLQ  5.00 4.80 96.0 2.22 1.20 –
QC  LOW 15.0 15.4 102.7 2.16 # 103 ± 1.19
QC  MIDDLE 100 103 103.0 1.65 0.47 –
QC  HIGH 400 381 95.3 1.80 2.04 100 ± 0.914
QC  DILUTED 8000 7509 93.9 3.39 # –
Nintedanib
LLQ  5.00 4.89 97.8 2.14 2.30 –
QC  LOW 15.0 14.4 96.0 2.02 2.53 99.9 ± 1.08
QC  MIDDLE 100 95.7 95.7 1.62 1.06 –
QC  HIGH 400 373 93.3 2.44 2.30 98.4 ± 2.40
QC  DILUTED 8000 7199 90.0 3.14 2.54 –
ditionAbbreviations: WRP  = within-run precision; BRP = between-run precision. # = no ad
mean  values ± standard deviation (n=3).3.2.3. Stability
All SMKIs were stable when the tested human plasma samples
where kept for three days at ambient temperature, kept for 23 h in
t
E
t
4
al variation observed by performing the assay in different runs. 1 = data representhe autosampler and freezed and thawed three subsequent times.
very sample fell within 15 % of nominal concentrations (which is
he FDA acceptance range [18]). These results are shown in Table 3.
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(A, D,
 the pFig. 2. Representative chromatograms of double blank processed plasma samples 
dacomitinib (E), lorlatinib (H), and nintedanib (K), and plasma samples collected in
37.3  ng/mL nintedanib (L) and internal standard dasatinib-d8 (F).Long-term stability was tested at the time this reported was writ-
ten. Since the ceritinib stock was stored earlier than the other SMKI
stocks, its long-term stability was at least 2 years and 8 months. For
d
l
5
 G and J), plasma samples spiked at the concentration of the LLQ for ceritinib (B),
harmacokinetic study containing 875 ng/mL ceritinib (C), 305 ng/mL lorlatinib (I),acomitinib, lorlatinib and nintedanib, long-term stability was at
east six months and is still ongoing.
G.D.M. Veerman, P. de Bruijn, A.-M.C. Dingemans et al. Journal of Pharmaceutical and Biomedical Analysis 193 (2021) 113733
Table  3
Stability after different storage conditions.
Reference 3 days Ambient Temp1 3 freeze-thaw-cycles1 Autosampler (23 h)2
Ceritinib
QC LOW 16.1 ± 0.529 14.3 ± 0.153 (89.0 %) 16.1 ± 0.458 (100 %) 16.2 (1.3 %)
QC  HIGH 434 ± 8.08 403 ± 16.6 (92.8 %) 429 ± 14.7 (98.8 %) 417 (96.3 %)
QC  DILUTED 8,214 ± 180 8,436 ± 160 (1.3 %) 9443 ± 279 (115 %) 8575 (98.9 %)
Dacomitinib
QC  LOW 15.0 ± 0.100 12.1 ± 0.058 (80.9 %) 13.6 ± 0.100 (90.7 %) 14.1 (97.9 %)
QC  HIGH 392 ± 8.96 343 ± 3.22 (87.3 %) 387 ± 7.94 (98.6 %) 374 (95.7 %)
QC  DILUTED 7,429 ± 376 7,112 ± 267 (95.7 %) 7834 ± 898 (106 %) 7482 (95.8 %)
Lorlatinib
QC  LOW 15.9 ± 0.611 15.6 ± 0.173 (98.3 %) 15.7 ± 0.100 (98.9 %) 15.3 (96.2 %)
QC  HIGH 396 ± 11.0 396 ± 4.04 (100 %) 396 ± 6.43 (99.8 %) 375 (91.2 %)
QC  DILUTED 7,770 ± 405 8,300 ± 266 (107 %) 8521 ± 107 (110 %) 7725 (93.3 %)
Nintedanib
QC  LOW 14.8 ± 0.379 14.1 ± 0.208 (94.8 %) 14.4 ± 0.493 (96.9 %) 15.1 (97.4 %)
QC  HIGH 382 ± 12.8 378 ± 13.9 (98.9 %) 387 ± 15.6 (104 %) 392 (94.9 %)
QC  DILUTED 7,477 ± 112 8,140 ± 175 (109 %) 
Data represent mean ± standard deviation (n = 3). 1 = versus value the reference. 2 = vers
Table 4
Incurred samples reanalysis.
Compound First analysis Second analysis Mean % Difference
Conc. (ng/mL) Conc. (ng/mL) Conc. (ng/mL) (%)
Ceritinib
1 818 875 847 −6.7
2  922 911 917 1.2
3  195 192 194 1.6
4  670 638 654 4.9
5  855 838 847 2.0
Nintedanib
1  15.0 15.2 15.1 −1.3
2  35.8 37.3 36.6 −4.1
3  11.2 12.1 11.7 −7.7
4  7.41 7.83 7.62 −5.5
Lorlatinib
1  300 305 303 −1.7
2  631 632 632 −0.2
3  335 361 348 −7.5
4  188 191 190 −1.6
5  36.0 38.7 37.4 −7.2
6  287 395 291 −2.7
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sis)*100.
3.3. Clinical applicability
Fifteen study samples were successfully used to prove the clini-
cal applicability of this assay. Respectively five, six and four plasma
samples of patients treated with ceritinib, lorlatinib and nintedanib
were processed and quantified. Table 4 presents the measured con-
centrations, which were all within this assay’s concentration range.
Only ceritinib and nintedanib have exploratory results indicat-
ing towards potential target concentrations which could be used
for therapeutic drug monitoring (TDM). [4] With TDM, dose opti-
mization and personalization could lead to higher efficacy and
lower toxicity of treatment with SMKIs. Further pharmacokinetic
research should therefore be focusing on whether or not there exist
solid target concentrations for treatment efficacy or toxicity. This
is necessary in order to use plasma drug concentrations for opti-
mization of treatment with these SMKIs in the future.
3.4. Incurred sample reanalysis
Reanalysing the patient samples did not result in significant
deviation in quantification (last columns of Table 4.). Hence all
SMKIs passed the incurred sample reanalysis test, in which the FDA
criteria for small-molecules is that at least two-thirds of the sam-
ples should have no more than 20 % difference between each other.
w
V
t
o
6
8462 ± 286 (1.3 %) 8020 (97.4 %)
us value “0h” (n = 1).
18] Ceritinib had an average 3.3 % difference (-6.7 to 4.9 %), which
as for lorlatinib 3.5 % (-7.5 to -0.2 %) and for nintedanib 4.7 % (-7.7
o -1.3 %).
.5. Performance comparison with other methods
There are multiple LC MS/MS  assays published which report
he quantification of ceritinib, [8–12] dacomitinib [13], lorlatinib
14], or nintedanib [15–17] in plasma, with similar quantification
oncentration ranges. For both ceritinib and nintedanib, method-
logies are described to quantify multiple SMKIs simultaneously
n human plasma [10,16]. However, only single SMKI LC MS/MS
ssays have been described for quantifying dacomitinib (LLQ 1.00
g/mL) and lorlatinib (LLQ 2.00 ng/mL) in non-human (rodent)
lasma. [13,14] In comparison to these latter methodologies, the
ere reported method is more efficient to quantify essential SMKIs
imultaneously and it is the first that is validated for human plasma.
t is important to extrapolate animal studies to human studies,
ince differences in validation and applicability could occur. In
he multi-assays for ceritinib and nintedanib, multiple (isotope-
abelled) internal standards are used. A compound has potential to
erve as an internal standard when is has (almost) equal chemical
haracteristics (e.g. boiling temperature and atomic groups) com-
ared to the compounds that have to be quantified. It is important
hat compound will not be present in the plasma samples though.
herefore, an isotope-labelled internal standard is often used for
very analyte. However, using one internal standard over using all
ifferent internal standards is besides financially attractive, also
ore efficient in preparation and storage, and reduces the influ-
nce of repeated random errors in preparation and quantification
f the internal standards. In this method, dasatinib-d8 was success-
ully used as internal standard because of its very similar chemical
haracteristics.
. Conclusion
This article reports the development and validation of the
rst ultra-performance liquid chromatography/tandem mass spec-
rometry (UPLC–MS/MS) method to simultaneously analyse the
MKIs dacomitinib, ceritinib, lorlatinib, and nintedanib in human
lasma, with dasatinib-d8 as sole internal standard. Calibration
urves for all SMKIs were linear in the range of 5.00–500 ng/mL.
ith a lower limit of quantitation of 5.00 ng/mL for all compounds.
alidation of this method met  all requirements of the FDA. Addi-
ionally, clinical applicability was demonstrated by quantification
f multiple samples from a pharmacokinetic study in lung cancer
[
[
[
[
[
[
[
[
[
[
[20] G.D.M. Veerman, M.H. Lam, R.H.J. Mathijssen, S.L.W. Koolen, P. de Bruijn,G.D.M. Veerman, P. de Bruijn, A.-M.C. Dingemans et al. 
patients. This method can hence be used in the future for TDM in a
clinical setting.
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